戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 o methicillin, cefotaxime, penicillin G, and nafcillin.
2 lerability of cefazolin after switching from nafcillin.
3  not tolerate cefazolin after switching from nafcillin.
4 riencing a suspected non-IgE-mediated HSR to nafcillin.
5  develop a suspected non-IgE-mediated HSR to nafcillin.
6                                              Nafcillin and cefazolin are considered first-line therap
7 ) days, respectively, for those treated with nafcillin and cefazolin.
8  non-IgE-mediated HSR that was attributed to nafcillin and discontinued cefazolin within 7 days.
9 ands, ethidium, rhodamine 6G, ciprofloxacin, nafcillin, and Phe-Arg-beta-naphthylamide.
10 riencing a suspected non-IgE-mediated HSR to nafcillin appears to be safe, even for patients requirin
11 ediated hypersensitivity reactions (HSRs) to nafcillin are commonly reported, but scarce data are ava
12                                In 9 cases of nafcillin discontinuation, treatment was changed to cefa
13 riptive case series of patients who received nafcillin for an MSSA infection, experienced a suspected
14  exclusion of such compounds, exemplified by nafcillin, from cells of the wild-type S. typhimurium wa
15                         More patients in the nafcillin group developed rash (13.9% vs 4.2%; P = .002)
16              Subinhibitory concentrations of nafcillin induced and prolonged mRNA for Panton-Valentin
17 nfections when patients experience an HSR to nafcillin, more data are needed to evaluate the tolerabi
18 ort analysis of patients treated with either nafcillin or cefazolin for MSSA infection in the outpati
19 sixty-six and 119 patients were treated with nafcillin or cefazolin, respectively.
20 ompared definitive therapy with cefazolin vs nafcillin or oxacillin among patients with MSSA infectio
21 r odds of recurrent infections compared with nafcillin or oxacillin for MSSA infections complicated b
22 efazolin compared with patients who received nafcillin or oxacillin, after controlling for other fact
23 I, .66-.90) compared with patients receiving nafcillin or oxacillin, after controlling for other fact
24 antistaphylococcal penicillin (oxacillin and nafcillin) or first-generation cephalosporin (cefazolin)
25  received definitive therapy with cefazolin, nafcillin, or oxacillin.
26                   First-line MSSA therapies (nafcillin, oxacillin, cefazolin) are generally avoided i
27 tion of vancomycin and a beta-lactam (either nafcillin, oxacillin, or cefazolin) for staphylococcal b
28                  PBP4 had a low affinity for nafcillin, reacted with a monoclonal antibody raised aga
29 leted the prespecified treatment course with nafcillin than with cefazolin (PAD rate, 33.8% vs 6.7%;
30                                              Nafcillin treatment was associated with higher rates of
31              The hazard ratio for PAD in the nafcillin vs cefazolin groups was 2.81 (95% confidence i